I2536

ICI 192605

≥98% (HPLC)

• Sinónimos: (4Z)-rel-, 4(Z)-6-(2-o-chlorophenyl-4-o-hydroxyphenyl-1,3-dioxan-cis-5-yl) hexenoic acid, 4-Hexenoic acid, 6-[(2R,4R,5S)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]-
• Fórmula empírica (notación de Hill): C₂₂H₂₃ClO₅
• Número de CAS: 117621-64-4
• Peso molecular: 402.87
• MDL number: MFCD00673936
• UNSPSC Code: 12352200
• PubChem Substance ID: 329815367
• NACRES: NA.77

Propiedades

• assay: ≥98% (HPLC)
• form: powder
• color: white to tan
• solubility: DMSO: ≥20 mg/mL
• originator: AstraZeneca
• storage temp.: −20°C
• SMILES string: OC(=O)CC\C=C/C[C@H]1CO[C@H](O[C@H]1c2ccccc2O)c3ccccc3Cl
• InChI: 1S/C22H23ClO5/c23-18-11-6-4-9-16(18)22-27-14-15(8-2-1-3-13-20(25)26)21(28-22)17-10-5-7-12-19(17)24/h1-2,4-7,9-12,15,21-22,24H,3,8,13-14H2,(H,25,26)/b2-1-/t15-,21+,22+/m0/s1
• InChI key: WHUIENZXNGAHQI-YGPRPMEGSA-N

Descripción

Biochem/physiol Actions

ICI 192605 is a potent thromboxane A2 receptor antagonist. It inhibits platelet aggregation and can reverse the effects of vasoconstrictors such as TXA2 or PGD2. ICI 192605 can reverse vasoconstriction induced by inhibition of NO production by L-NEMA, which leads to an increase in TXA2 release.

Features and Benefits

This compound is featured on the Prostanoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• pictograms: GHS07,GHS09
• signalword: Warning
• hcodes: H302,H410
• pcodes: P264 - P270 - P273 - P301 + P312 - P391 - P501
• Hazard Classifications: Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1
• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable